bpi semaglutide GobyMeds - Compounded dose program helps you feel fuller and maintain a healthy weight Hometown - Exciting news! We

Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

& Cartmell, E

Lee SH, Min SH, Cho YC, Han JH, Kim MN, Kim CR, et al

Tirzepatide causes gastrointestinal side effects (nausea, vomiting, diarrhoea) in 3045% of patients during dose titration, typically resolving within 48 weeks

The Verdict: May offer short-term appetite effects, but unlikely to provide significant weight loss when used alone

At Endocare, every patient on a GLP-1 medication is supported by: A consultant endocrinologist who selects and adjusts the medication based on lab results, side-effect tolerance, and progress